IBDEI0KI ; ; 06-AUG-2015
 ;;3.0;IB ENCOUNTER FORM IMP/EXP;;JUN 29, 2015
 Q:'DIFQR(358.3)  F I=1:2 S X=$T(Q+I) Q:X=""  S Y=$E($T(Q+I+1),4,999),X=$E(X,4,999) S:$A(Y)=126 I=I+1,Y=$E(Y,2,999)_$E($T(Q+I+1),5,99) S:$A(Y)=61 Y=$E(Y,2,999) X NO E  S @X=Y
Q Q
 ;;^UTILITY(U,$J,358.3,9711,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9711,1,2,0)
 ;;=2^Ranibizumab Inj per 0.1mg
 ;;^UTILITY(U,$J,358.3,9711,1,3,0)
 ;;=3^J2778
 ;;^UTILITY(U,$J,358.3,9712,0)
 ;;=J3301^^43^555^4^^^^1
 ;;^UTILITY(U,$J,358.3,9712,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9712,1,2,0)
 ;;=2^Kenalog Inj per 10mg
 ;;^UTILITY(U,$J,358.3,9712,1,3,0)
 ;;=3^J3301
 ;;^UTILITY(U,$J,358.3,9713,0)
 ;;=J0178^^43^555^2^^^^1
 ;;^UTILITY(U,$J,358.3,9713,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9713,1,2,0)
 ;;=2^Aflibercept Inj 1mg
 ;;^UTILITY(U,$J,358.3,9713,1,3,0)
 ;;=3^J0178
 ;;^UTILITY(U,$J,358.3,9714,0)
 ;;=4450F^^43^556^2^^^^1
 ;;^UTILITY(U,$J,358.3,9714,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9714,1,2,0)
 ;;=2^Self-Care Ed Provided to Pt
 ;;^UTILITY(U,$J,358.3,9714,1,3,0)
 ;;=3^4450F
 ;;^UTILITY(U,$J,358.3,9715,0)
 ;;=4177F^^43^556^3^^^^1
 ;;^UTILITY(U,$J,358.3,9715,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9715,1,2,0)
 ;;=2^Talk Pt/Crgvr Re AREDS
 ;;^UTILITY(U,$J,358.3,9715,1,3,0)
 ;;=3^4177F
 ;;^UTILITY(U,$J,358.3,9716,0)
 ;;=4174F^^43^556^1^^^^1
 ;;^UTILITY(U,$J,358.3,9716,1,0)
 ;;=^358.31IA^3^2
 ;;^UTILITY(U,$J,358.3,9716,1,2,0)
 ;;=2^Couns Potent Glauc Impct
 ;;^UTILITY(U,$J,358.3,9716,1,3,0)
 ;;=3^4174F
 ;;^UTILITY(U,$J,358.3,9717,0)
 ;;=373.32^^44^557^48
 ;;^UTILITY(U,$J,358.3,9717,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9717,1,3,0)
 ;;=3^Eyelid,Dermatitis,Allergic
 ;;^UTILITY(U,$J,358.3,9717,1,4,0)
 ;;=4^373.32
 ;;^UTILITY(U,$J,358.3,9717,2)
 ;;=^269061
 ;;^UTILITY(U,$J,358.3,9718,0)
 ;;=373.00^^44^557^4
 ;;^UTILITY(U,$J,358.3,9718,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9718,1,3,0)
 ;;=3^Blepharitis
 ;;^UTILITY(U,$J,358.3,9718,1,4,0)
 ;;=4^373.00
 ;;^UTILITY(U,$J,358.3,9718,2)
 ;;=Blepharitis^15271
 ;;^UTILITY(U,$J,358.3,9719,0)
 ;;=373.2^^44^557^7
 ;;^UTILITY(U,$J,358.3,9719,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9719,1,3,0)
 ;;=3^Chalazion
 ;;^UTILITY(U,$J,358.3,9719,1,4,0)
 ;;=4^373.2
 ;;^UTILITY(U,$J,358.3,9719,2)
 ;;=^22156
 ;;^UTILITY(U,$J,358.3,9720,0)
 ;;=374.84^^44^557^29
 ;;^UTILITY(U,$J,358.3,9720,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9720,1,3,0)
 ;;=3^Eyelid Cysts
 ;;^UTILITY(U,$J,358.3,9720,1,4,0)
 ;;=4^374.84
 ;;^UTILITY(U,$J,358.3,9720,2)
 ;;=^269119
 ;;^UTILITY(U,$J,358.3,9721,0)
 ;;=374.87^^44^557^31
 ;;^UTILITY(U,$J,358.3,9721,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9721,1,3,0)
 ;;=3^Eyelid Dermatochalasis
 ;;^UTILITY(U,$J,358.3,9721,1,4,0)
 ;;=4^374.87
 ;;^UTILITY(U,$J,358.3,9721,2)
 ;;=^269123
 ;;^UTILITY(U,$J,358.3,9722,0)
 ;;=375.15^^44^557^12
 ;;^UTILITY(U,$J,358.3,9722,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9722,1,3,0)
 ;;=3^Dry Eye Syndrome
 ;;^UTILITY(U,$J,358.3,9722,1,4,0)
 ;;=4^375.15
 ;;^UTILITY(U,$J,358.3,9722,2)
 ;;=Dry Eye Syndrome^37168
 ;;^UTILITY(U,$J,358.3,9723,0)
 ;;=374.01^^44^557^20
 ;;^UTILITY(U,$J,358.3,9723,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9723,1,3,0)
 ;;=3^Entropion, Senile
 ;;^UTILITY(U,$J,358.3,9723,1,4,0)
 ;;=4^374.01
 ;;^UTILITY(U,$J,358.3,9723,2)
 ;;=Entropion, Senile^269074
 ;;^UTILITY(U,$J,358.3,9724,0)
 ;;=375.20^^44^557^68
 ;;^UTILITY(U,$J,358.3,9724,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9724,1,3,0)
 ;;=3^Lacrimal,Epiphora
 ;;^UTILITY(U,$J,358.3,9724,1,4,0)
 ;;=4^375.20
 ;;^UTILITY(U,$J,358.3,9724,2)
 ;;=Epiphora^269136
 ;;^UTILITY(U,$J,358.3,9725,0)
 ;;=373.11^^44^557^63
 ;;^UTILITY(U,$J,358.3,9725,1,0)
 ;;=^358.31IA^4^2
 ;;^UTILITY(U,$J,358.3,9725,1,3,0)
 ;;=3^Hordeolum Externum
 ;;^UTILITY(U,$J,358.3,9725,1,4,0)
 ;;=4^373.11
 ;;^UTILITY(U,$J,358.3,9725,2)
 ;;=^58510
 ;;
 ;;$END ROU IBDEI0KI
